Group 1 - The core point of the article is that Xuan Bamboo Biotech-B (02575) has seen a stock price increase following the announcement that its innovative drug, Pirlosil, has been included in the 2025 National Basic Medical Insurance Directory [1] - As of the report, the stock price rose by 1.98% to HKD 66.95, with a trading volume of HKD 15.1953 million [1] - The inclusion of Pirlosil in the insurance directory is expected to enhance its affordability and accessibility for patients, which will positively impact the drug's market promotion and sales growth [1] Group 2 - The 2025 National Basic Medical Insurance Directory will officially take effect on January 1, 2026 [1] - The company plans to actively support the implementation of the insurance policy, continue hospital access efforts, and expand its core market to improve patient access to medication [1] - This development is viewed as beneficial for the company's long-term operational growth [1]
港股异动 | 轩竹生物-B(02575)涨近3% 自研创新药轩悦宁®首次纳入2025国家基本医保目录